Fig. 1 · Structure

Documents & Downloads

BAPTA/AM

Cat. No. A14023 CAS 126150-97-8

Selective calcium chelator

BAPTA/AM, an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures.

In Stock

Publications for BAPTA/AM

7 publications citing this product

  1. Maohuan Ran, .et al. , Ecotoxicol Environ Saf, 2026, May:316:120163 PMID: 42013791
  2. Jian Sun, .et al. , Nanoscale, 2024, Dec 17 PMID: 39688368
  3. Jiunn-Chang Lin, .et al. , Toxicol Appl Pharmacol, 2023, Jul 15;471:116568 PMID: 37245555
  4. Liying Wu, .et al. , Phytother Res, 2022, Feb;36(2):938-950 PMID: 35076979
  5. Shichen Xu, .et al. , Cell Signal, 2020, Aug 6;75:109733 PMID: 32771398
  6. Miho Akimoto, .et al. , Cell Death Dis, 2018, Aug; 9(8): 804 PMID: 30038429
  7. Zhang L, .et al. , Medicine (Baltimore), 2018, Jun;97(24):e11095 PMID: 29901626

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

BAPTA-AM loading can suppress intercellular calcium-wave propagation. In rat astrocytic cultures, wave spread was blocked while stimulated cells retained a local calcium response. [1]

Calcium chelation does not explain every cellular response to BAPTA-AM. In canine ventricular myocytes, acute IKr inhibition occurred despite intracellular BAPTA buffering. [2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

In MIAPaCa-2 cells, BAPTA-AM partially attenuated AdipoRon-associated loss of MTT signal. Its own reduction of the vehicle-group signal and nonmonotonic response limit a simple rescue interpretation. [3]

Suppression of astrocytic calcium-wave propagation

Cell-based study · Rat forebrain mixed cultures, 14–21 days in vitro; neuron-free or sparse fields [1]

BAPTA-AM loading suppressed propagation while a local calcium response remained.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Failure to propagate a calcium waveQualitative propagation outcome Propagation blocked at 30 μM and strongly suppressed at 10 μM; local initial calcium response persisted[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 or 30 μM
Exposure duration
1.5 h loading at 37°C; imaging after rinse
Method
Fluo-3 imaging after mechanical stimulation
Vehicle
DMSO ≤0.25%; 0.01% pluronic during loading
Co-treatment
5 μM fluo-3 AM; indicator-only controls; lower-affinity analog comparisons
Reported limits
Intracellular BAPTA concentration was not quantified.
Methods and source locations

Compound reported in the paper: BAPTA-AM; Compound label in the paper: BAPTA-AM

Reported AM-ester reagent; supplier attribution does not validate the current catalog lot.

Results: An exogenous Ca2+ chelator blocks astrocytic Ca2+ waves; Figure 1; Methods: loading/imaging

Failure to propagate a calcium wave: Fluo-3 fluorescence — Results: An exogenous Ca2+ chelator blocks astrocytic Ca2+ waves; Figure 1A

Partial modification of AdipoRon-associated MTT loss

Cell-based study · Human MIAPaCa-2 pancreatic cancer cells [3]

Partial attenuation of AdipoRon-associated MTT loss coexisted with lower signal in BAPTA-AM-only controls.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MTT-based survival in AdipoRon and vehicle groupsQualitative figure outcome Partial, nonmonotonic attenuation; BAPTA-AM alone also lowered MTT signal[3]

Literature-Reported Treatment Conditions

Treatment concentration
0, 1, 2 or 5 μM
Exposure duration
1 h pretreatment, then 40 h with AdipoRon or vehicle
Method
MTT assay
Vehicle
AdipoRon solvent: DMSO; BAPTA-AM solvent not specified
Co-treatment
100 μM AdipoRon or vehicle
Reported limits
Independent biological replicate number not specified for Figure 3B; Methods describes triplicate wells.
Methods and source locations

Compound reported in the paper: BAPTA-AM; Compound label in the paper: BAPTA-AM

Reported AM-ester reagent; supplier attribution does not validate the current catalog lot.

Figure 3B and caption; Reagents; Cell growth and viability assay; Statistics

MTT-based survival in AdipoRon and vehicle groups: MTT absorbance at 550 nm — Figure 3B; Cell growth and viability assay

Acute inhibition of native cardiac IKr

Cell-based study · Isolated canine ventricular myocytes; conventional whole-cell voltage clamp at 37°C [2]

Acute IKr suppression persisted with intracellular BAPTA buffering.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
IKr tail-current densityMean ± SEM; n = 5 myocytes 0.39 ± 0.05 to 0.12 ± 0.03 A/F (32 ± 8% of control), P < 0.05; washout: 76 ± 5% of control[2]

Literature-Reported Treatment Conditions

Treatment concentration
5 μM external BAPTA-AM
Exposure duration
5 min exposure; 5 min washout
Method
Conventional voltage clamp
Vehicle
DMSO stock diluted into bath; final vehicle control not separately specified
Co-treatment
10 mM BAPTA in pipette; 1 μM nisoldipine and 1 μM HMR 1556 in bath
Reported limits
No concentration-response IC50 determined in this adopted design.
Methods and source locations

Compound reported in the paper: BAPTA-AM; Compound label in the paper: BAPTA-AM

Reported AM-ester reagent; supplier attribution does not validate the current catalog lot.

Figure 6; Results: Effect of BAPTA-AM on IKr current; Methods: Conventional voltage clamp

IKr tail-current density: Tail current on repolarization to −40 mV — Results: Effect of BAPTA-AM on IKr current, first paragraph; Figure 6

In Vivo Studies

Topical cortical BAPTA-AM reduced one-day infarct volume in a mouse photothrombotic ischemia experiment. This local-delivery result does not establish systemic efficacy or astrocyte-exclusive action. [4]

Local cortical delivery and infarct volume

Animal study · Male FVB/NJ mice, 5–7 weeks; bilateral cortical ischemia [4]

Local BAPTA-AM was associated with reduced one-day infarct volume.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Nissl-defined infarct volumeRelative reduction 47%; N = 6 mice; p < 0.05 (t-test)[4]

Conditions shared by the study groups

Route
Topical cortical application through a cranial window
Frequency
Applied after photothrombosis; repeat schedule not specified
Treatment course
Endpoint one day after ischemia
Vehicle
Premelted agarose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Local BAPTA-AM versus contralateral carrier
200 μM BAPTA-AM in agarose (local formulation concentration)
Contralateral cranial window received agarose without BAPTA-AMReported 47% smaller infarct volume; N = 6 mice; p < 0.05[4]
Local BAPTA-AM versus contralateral carrier
Model: Male FVB/NJ mice, 5–7 weeks; bilateral cortical photothrombotic ischemia
Reported limits: Applied volume and mass dose not reported in the BAPTA paragraph; randomization/blinding not specified there.
Methods and source locations

Compound reported in the paper: BAPTA-AM; Compound label in the paper: BAPTA-AM

Reported AM-ester reagent; supplier attribution does not validate the current catalog lot.

Results: Brain protection by selective attenuation of astrocytic Ca2+ signal (BAPTA paragraph); Figure 6; Methods: Infarct volume estimation, Animals, Statistical analysis

Nissl-defined infarct volume: Serial-section Nissl staining and ImageJ area integration — BAPTA Results paragraph; Figure 6C; Infarct volume estimation

Local BAPTA-AM versus contralateral carrier · Results: Brain protection by selective attenuation of astrocytic Ca2+ signal (BAPTA paragraph); Figure 6; Methods: Infarct volume estimation, Animals, Statistical analysis

Specifications

Manufacturer Adooq Bioscience
CAS Number 126150-97-8
Applications Selective calcium chelator
Formula C34H40N2O18
Molecular Weight 764.68
Synonyms BAPTA-AM
SMILES
CC(=O)OCOC(=O)CN(CC(=O)OCOC(=O)C)C1=CC=CC=C1OCCOC2=CC=CC=C2N(CC(=O)OCOC(=O)C)CC(=O)OCOC(=O)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 19 mg/mL (24.84 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Wang Z, Tymianski M, Jones OT, et al. Impact of cytoplasmic calcium buffering on the spatial and temporal characteristics of intercellular calcium signals in astrocytes. The Journal of neuroscience : the official journal of the Society for Neuroscience (1997). PMID: 9295382 DOI: 10.1523/jneurosci.17-19-07359.1997 Source material
  2. [2] Horvath B, Szentandrassy N, Veress R, et al. Effect of the intracellular calcium concentration chelator BAPTA acetoxy-methylester on action potential duration in canine ventricular myocytes. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (2018). PMID: 29769426 DOI: 10.26402/jpp.2018.1.11 Source material
  3. [3] Akimoto M, Maruyama R, Kawabata Y, et al. Antidiabetic adiponectin receptor agonist AdipoRon suppresses tumour growth of pancreatic cancer by inducing RIPK1/ERK-dependent necroptosis. Cell death & disease (2018). PMID: 30038429 DOI: 10.1038/s41419-018-0851-z Source material
  4. [4] Ding S, Wang T, Cui W, et al. Photothrombosis ischemia stimulates a sustained astrocytic Ca2+ signaling in vivo. Glia (2009). PMID: 18985731 DOI: 10.1002/glia.20804 Source material

Publications

7 publications citing this product

  1. Maohuan Ran, .et al. , Ecotoxicol Environ Saf, 2026, May:316:120163 PMID: 42013791
  2. Jian Sun, .et al. , Nanoscale, 2024, Dec 17 PMID: 39688368
  3. Jiunn-Chang Lin, .et al. , Toxicol Appl Pharmacol, 2023, Jul 15;471:116568 PMID: 37245555
  4. Liying Wu, .et al. , Phytother Res, 2022, Feb;36(2):938-950 PMID: 35076979
  5. Shichen Xu, .et al. , Cell Signal, 2020, Aug 6;75:109733 PMID: 32771398
  6. Miho Akimoto, .et al. , Cell Death Dis, 2018, Aug; 9(8): 804 PMID: 30038429
  7. Zhang L, .et al. , Medicine (Baltimore), 2018, Jun;97(24):e11095 PMID: 29901626

Added to your cart

View Cart Checkout
Loading...